FAQ

turoctocog alfa

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
024620122018

Related topics

Related topics

2 relations

Broader (1)

Factor VIII

Narrower (1)

Novoeight

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
turoctocog alfa
Factor VIII
Novoeight

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2015
Review
2015
The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
BACKGROUND Turoctocog alfa (NovoEight(®)) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2015
Review
2015
Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine… (More)
Is this relevant?
Review
2014
Review
2014
Turoctocog alfa (NovoEight®) – from design to clinical proof of concept
Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
Review
2014
Review
2014
Turoctocog alfa for the treatment of hemophilia a.
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor… (More)
Is this relevant?
2014
2014
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
Haemophilia and its treatment interfere with patients' life, so health-related quality of life (HRQoL) should be assessed when… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2014
Review
2014
Turoctocog alfa for the treatment of hemophilia A.
Patients with hemophilia A lack functional coagulation factor VIII (FVIII), causing excessive spontaneous bleeding episodes and… (More)
Is this relevant?
2013
2013
Results from a large multinational clinical trial (guardianâ„¢1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and…
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… (More)
Is this relevant?
2012
2012
Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
The objective of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the new… (More)
Is this relevant?